Advertisement

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer
Posted: 01/09/2026 | By: Custom Content Editorial

A recent phase III randomized trial, ASCENT-30, compared sacituzumab govitecan with chemotherapy in patients with previously untreated, advanced triple-negative breast cancer. Take this quiz to test your knowledge of the study results, which were presented at the ESMO Congress 2025 and published in The New England Journal of Medicine .

Question 1 of 5

Which patients were eligible for enrollment in the ASCENT-03 clinical trial?

Choose 1

A
Patients with hormone receptor–positive metastatic breast cancer
B
Patients with previously untreated, resectable early-stage triple-negative breast cancer
C
Patients with triple-negative breast cancer whose disease had progressed after immunotherapy
D
Patients with newly diagnosed, advanced triple-negative breast cancer who were not candidates for programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage